Join the Newsletter
SEARCH
Loading
Search Filters
  • Speakers
  • Audience
  • Topic
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
12:45 PM
  1. Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems
    Theatre 2
    30 mins
    • Operational & Commercial Performance
     
    Francis Pang
    Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
    Peter Fassler
    Peter Fassler, Director Market Access - Gilead Sciences
    Tamara Loos
    Tamara Loos, Consultant - ENIMAXE
01:15 PM
  1. Lunch
    Exhibition Hall
    75 mins
    • Networking Break
     
01:30 PM
  1. Designing advanced therapies that survive scale: from early decisions to commercial readiness
    Workshop Room
    60 mins
    • Workshop
    Advanced therapy developers face intense pressure to accelerate timelines, but speed without early discipline across CMC, delivery, analytics, and manufacturing can introduce risks that surface later ...
    Cytiva
02:30 PM
  1. Spotlight: Starting materials at scale – Viral Vectors, LNPs and the economics of editing
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
  2. Spotlight: QC under pressure - Sterility, potency and release for products with hours, not weeks
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
02:45 PM
  1. Spotlight: : Enabling IV, brain-wide AAV gene delivery through an FDA-informed, GMP-ready platform
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
    Jorge Santiago-Ortiz
    Jorge Santiago-Ortiz, VP, CMC & Regulatory Affairs - Apertura Gene Therapy
  2. Spotlight: Consistency by design: Applying annex 1 and modern QC strategies to Global platform CGT manufacturing with aligned fast QC release
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
    Charlotte Serra
    Charlotte Serra, President - RAPS Switzerland Chapter
03:00 PM
  1. Spotlight: Engineering safety at scale: How next-generation AAV manufacturing is tackling yield, consistency and toxicity risk together
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
    Why scaling AAV is still hard: The recurring technical bottlenecks seen across programmes—spanning upstream productivity, downstream resolution, analytics and batch-to-batch variability. Manufacturing ...
  2. Panel: From bottleneck to enabler: Rethinking QC strategies for cell and gene therapy manufacturing
    Theatre 2
    30 mins
    • Operational & Commercial Performance
     
    Charlotte Serra
    Charlotte Serra, President - RAPS Switzerland Chapter
    Lindsay Davies
    Lindsay Davies, CSO - NextCell Pharma
    Stefano Baila
    Stefano Baila, Consultant - SJBIOconsulting
03:15 PM
  1. Fireside chat: AAV at scale without compromise: How the field is fixing manufacturing bottlenecks and toxicity risk without slowing clinical momentum
    Theatre 1
    30 mins
    • Cell & Gene Therapy Clinical Pathways
    AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the eff ...
    Jorge Santiago-Ortiz
    Jorge Santiago-Ortiz, VP, CMC & Regulatory Affairs - Apertura Gene Therapy
03:30 PM
  1. Spotlight: De-risking MSC scale-up: 4 Platform strategies from R&D to stem cell production
    Theatre 2
    15 mins
    • Operational & Commercial Performance
    Scaling MSC manufacturing remains a major challenge in cell therapy development, particularly as processes move from early research into clinical and commercial production. This presentation reviews f ...
    Nicolas Andre
    Nicolas Andre, Director Field Applications, EMEA - Corning Life Sciences
03:45 PM
  1. Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?
    Theatre 1
    30 mins
    • Cell & Gene Therapy Clinical Pathways
    The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
    Margot Pont
    Margot Pont, VP Translational Development - Integra Therapeutics
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
  2. Spotlight: Building for the long game: What it really takes to industrialise cell & gene therapy at scale
    Theatre 2
    15 mins
    • Operational & Commercial Performance
    Why the old production model breaks: What Roche learned about the limits of legacy CGT manufacturing cost, throughput, flexibility and why incremental upgrades were no longer enough. Inside Penzberg: ...
    Bo Wiinberg
    Bo Wiinberg, CBO - Novo Nordisk Foundation Cellerator
04:00 PM
  1. Spotlight: Chain of identity at scale – the supply chain challenge that hasn’t gone away
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
    Johanna Goldmann
    Johanna Goldmann, Business Development Manager - ProBioGen
04:15 PM
  1. Break
    Exhibition Hall
    30 mins
     
04:45 PM
  1. Roundtable: Patents without regret: When to file, when to wait, and when to license avoiding IP decisions that limit future value
    Workshop Room
    45 mins
    • Roundtable
  2. Roundtable: From bench to build: How academic scientists turn ideas into fundable biotechs
    Workshop Room
    45 mins
    • Roundtable
    Laura Koivusalo
    Laura Koivusalo, CEO - StemSight
  3. Roundtable: Choosing Your Modality Early and Living With It: How platform, delivery and indication choices shape timelines, capital needs and exit options
    Workshop Room
    45 mins
    • Roundtable
  4. Roundtable: Creating visibility across the patient cell journey: Building customer engagement into CAR-T operations
    Workshop Room
    45 mins
    • Roundtable
    Danny Evans
    Danny Evans, Customer experience & commercial operations expert, Advanced Therapies - Lima Lime Consulting
  5. Roundtable: Public–private partnership models that combine academic, clinical, and industry strengths to accelerate translation of advanced therapies
    Workshop Room
    45 mins
    • Roundtable
    Simon de Miquel
    Simon de Miquel, Strategic Project Manager & Business Developer - Advanced Therapies - Barcelona Children's Hospital Sant Joan de Deu
Loading
Search Filters
  • Speakers
  • Audience
  • Topic
We're sorry, but we couldn't find any results that match your search criteria. Please try again with different keywords or filters.
Loading
12:45 PM
  1. Panel: From scaled to standard of care: commercialising CGTs across Europe’s fragmented health systems
    Theatre 2
    30 mins
    • Operational & Commercial Performance
     
    Francis Pang
    Francis Pang, Senior Vice President, Global Market Access and International Geographic Expansion - Orchard Therapeutics
    Peter Fassler
    Peter Fassler, Director Market Access - Gilead Sciences
    Tamara Loos
    Tamara Loos, Consultant - ENIMAXE
01:15 PM
  1. Lunch
    Exhibition Hall
    75 mins
    • Networking Break
     
01:30 PM
  1. Designing advanced therapies that survive scale: from early decisions to commercial readiness
    Workshop Room
    60 mins
    • Workshop
    Advanced therapy developers face intense pressure to accelerate timelines, but speed without early discipline across CMC, delivery, analytics, and manufacturing can introduce risks that surface later ...
    Cytiva
02:30 PM
  1. Spotlight: Starting materials at scale – Viral Vectors, LNPs and the economics of editing
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
  2. Spotlight: QC under pressure - Sterility, potency and release for products with hours, not weeks
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
02:45 PM
  1. Spotlight: : Enabling IV, brain-wide AAV gene delivery through an FDA-informed, GMP-ready platform
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
     
    Jorge Santiago-Ortiz
    Jorge Santiago-Ortiz, VP, CMC & Regulatory Affairs - Apertura Gene Therapy
  2. Spotlight: Consistency by design: Applying annex 1 and modern QC strategies to Global platform CGT manufacturing with aligned fast QC release
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
    Charlotte Serra
    Charlotte Serra, President - RAPS Switzerland Chapter
03:00 PM
  1. Spotlight: Engineering safety at scale: How next-generation AAV manufacturing is tackling yield, consistency and toxicity risk together
    Theatre 1
    15 mins
    • Cell & Gene Therapy Clinical Pathways
    Why scaling AAV is still hard: The recurring technical bottlenecks seen across programmes—spanning upstream productivity, downstream resolution, analytics and batch-to-batch variability. Manufacturing ...
  2. Panel: From bottleneck to enabler: Rethinking QC strategies for cell and gene therapy manufacturing
    Theatre 2
    30 mins
    • Operational & Commercial Performance
     
    Charlotte Serra
    Charlotte Serra, President - RAPS Switzerland Chapter
    Lindsay Davies
    Lindsay Davies, CSO - NextCell Pharma
    Stefano Baila
    Stefano Baila, Consultant - SJBIOconsulting
03:15 PM
  1. Fireside chat: AAV at scale without compromise: How the field is fixing manufacturing bottlenecks and toxicity risk without slowing clinical momentum
    Theatre 1
    30 mins
    • Cell & Gene Therapy Clinical Pathways
    AAV demand has outpaced infrastructure: Why current production models struggle to meet clinical and commercial demand and which upstream, downstream and process innovations are finally closing the eff ...
    Jorge Santiago-Ortiz
    Jorge Santiago-Ortiz, VP, CMC & Regulatory Affairs - Apertura Gene Therapy
03:30 PM
  1. Spotlight: De-risking MSC scale-up: 4 Platform strategies from R&D to stem cell production
    Theatre 2
    15 mins
    • Operational & Commercial Performance
    Scaling MSC manufacturing remains a major challenge in cell therapy development, particularly as processes move from early research into clinical and commercial production. This presentation reviews f ...
    Nicolas Andre
    Nicolas Andre, Director Field Applications, EMEA - Corning Life Sciences
03:45 PM
  1. Panel: The in vivo inflection: From breakthrough to clinical momentum, how far and how fast can this wave go?
    Theatre 1
    30 mins
    • Cell & Gene Therapy Clinical Pathways
    The inflection is measurable: What recent in vivo clinical readouts are showing about delivery efficiency, expression control and safety—and where performance is becoming reproducible rather than exce ...
    Margot Pont
    Margot Pont, VP Translational Development - Integra Therapeutics
    Stefanos Theoharis
    Stefanos Theoharis, CEO - OneChain Immunotherapeutics
  2. Spotlight: Building for the long game: What it really takes to industrialise cell & gene therapy at scale
    Theatre 2
    15 mins
    • Operational & Commercial Performance
    Why the old production model breaks: What Roche learned about the limits of legacy CGT manufacturing cost, throughput, flexibility and why incremental upgrades were no longer enough. Inside Penzberg: ...
    Bo Wiinberg
    Bo Wiinberg, CBO - Novo Nordisk Foundation Cellerator
04:00 PM
  1. Spotlight: Chain of identity at scale – the supply chain challenge that hasn’t gone away
    Theatre 2
    15 mins
    • Operational & Commercial Performance
     
    Johanna Goldmann
    Johanna Goldmann, Business Development Manager - ProBioGen
04:15 PM
  1. Break
    Exhibition Hall
    30 mins
     
04:45 PM
  1. Roundtable: Patents without regret: When to file, when to wait, and when to license avoiding IP decisions that limit future value
    Workshop Room
    45 mins
    • Roundtable
  2. Roundtable: From bench to build: How academic scientists turn ideas into fundable biotechs
    Workshop Room
    45 mins
    • Roundtable
    Laura Koivusalo
    Laura Koivusalo, CEO - StemSight
  3. Roundtable: Choosing Your Modality Early and Living With It: How platform, delivery and indication choices shape timelines, capital needs and exit options
    Workshop Room
    45 mins
    • Roundtable
  4. Roundtable: Creating visibility across the patient cell journey: Building customer engagement into CAR-T operations
    Workshop Room
    45 mins
    • Roundtable
    Danny Evans
    Danny Evans, Customer experience & commercial operations expert, Advanced Therapies - Lima Lime Consulting
  5. Roundtable: Public–private partnership models that combine academic, clinical, and industry strengths to accelerate translation of advanced therapies
    Workshop Room
    45 mins
    • Roundtable
    Simon de Miquel
    Simon de Miquel, Strategic Project Manager & Business Developer - Advanced Therapies - Barcelona Children's Hospital Sant Joan de Deu
Search